Triple Fit Group Limited (02526) is planning to globally offer 7.9992 million H shares for subscription from March 20th to March 25th.

Dezhi-B (02526) will be listed for public offering from March 20, 2026 to March 25, 2026, planning to globally issue 7.9992 million H shares, with around 10% to be offered in Hong Kong and approximately 90% for international offering. The offering price per share is between 95.6 to 112.5 Hong Kong dollars. Each lot consists of 50 H shares, and it is expected that the H shares will start trading on the Stock Exchange on Monday, March 30, 2026 at 9:00 am. The group is a medical device company focused on developing medical imaging products and services. It has developed a diversified product portfolio, including six medical imaging software products (one core product in the registration phase AI AutoVision, one commercialized product AutoVision, and four other pre-clinical stage medical imaging software candidate products), three commercialized medical devices, four main reagents and consumables, and two technology licensed products. The core product AI AutoVision is a chromosomal karyotype diagnostic software designed for intelligent analysis of chromosomal karyotype. The group plans to sell this software by providing customized computers with pre-installed software in China and globally. AI AutoVision is expected to be used for prenatal diagnosis of birth defects using amniotic fluid samples and chromosomal karyotype analysis for reproductive diagnostics using peripheral blood samples. It is intended to be approved for use in birth defect prevention, pre-marital and pre-pregnancy screening, and reproductive assistance, among other areas. Assuming the offering price is 104.1 Hong Kong dollars per H share (i.e. the midpoint of the indicative offering price range as stated in this Prospectus), after deducting underwriting commissions, expenses, and estimated expenses payable by the group for the global offering, the group estimates that it will receive net proceeds of approximately 763 million Hong Kong dollars from the global offering. Assuming the offering price is the midpoint of the indicative offering price range, the group intends to allocate the net proceeds as follows: approximately 49.0% to be allocated to the research and commercialization of the group's core product AI AutoVision, approximately 10.0% to be allocated over the next three years post-listing to further research and development of the group's other medical imaging software candidate products and medical devices, approximately 20.0% to strengthen the group's iMedImage platform model and AI technology, approximately 8.0% to enhance the group's commercial capabilities and market penetration in China, approximately 5.0% to expand the group's global market presence by hiring about two junior local sales representatives, eight mid-level local sales representatives, and nine senior local sales representatives, and approximately 8.0% to seek strategic cooperation and investment opportunities with participants in the medical value chain. The group believes that its financial performance and future growth depend on the overall growth of the intelligent medical imaging market. With the increase in demand, advancements in AI technology, development of hospital information systems, and favorable policies, the market size of China's intelligent medical imaging market is expected to increase to 401 billion yuan by 2030, with a compound annual growth rate of 60.2% from 2024 to 2030, further increasing to 781 billion yuan by 2035, with a compound annual growth rate of 14.2% from 2030 to 2035.